Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03642626 · ClinicalTrials.gov registry record · Phase 2
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
A Phase 2 study of Acute Lymphoblastic Leukemia and Large B-cell Lymphoma, sponsored by Masonic Cancer Center, University of Minnesota.
- Active
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT03642626: Active Phase 2 study of Acute Lymphoblastic Leukemia and Large B-cell Lymphoma, sponsored by Masonic Cancer Center, University of Minnesota.
NCT03642626 is a Phase 2 study of Acute Lymphoblastic Leukemia and Large B-cell Lymphoma that is active but no longer recruiting, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 150 participants, below the 381-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03642626, a Phase 2 study of Acute Lymphoblastic Leukemia and Large B-cell Lymphoma, is active but no longer recruiting, sponsored by Masonic Cancer Center, University of Minnesota.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.
Primary Outcome
ORR defined by complete response + partial response by Lugano
Conditions Studied
Interventions
- DRUG KYMRIAH
- DRUG YESCARTA
- DRUG Fludarabine 30mg/m2 4 doses
- DRUG Cyclophosphamide 500 mg/m2; 2 doses
- DRUG Fludarabine 30mg/m2 3 doses
Study Locations (1)
Minnesota
- Masonic Cancer Center at University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-12-18 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 2 |
What the registry record for NCT03642626 still lists
NCT03642626 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 381-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (61% lower).
The record links to 2 conditions, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 5 interventions - of which KYMRIAH is the first listed.
NCT03642626 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT03642626 about?
NCT03642626 is a clinical study titled "MT2017-45: CAR-T Cell Therapy for Heme Malignancies". This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.
What is the current status of trial NCT03642626?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2018-12-18. Estimated completion is 2028-06-01.
What conditions does trial NCT03642626 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Large B-cell Lymphoma.
What interventions are being tested in trial NCT03642626?
The interventions under investigation include: KYMRIAH (DRUG), YESCARTA (DRUG), Fludarabine 30mg/m2 4 doses (DRUG), Cyclophosphamide 500 mg/m2; 2 doses (DRUG), Fludarabine 30mg/m2 3 doses (DRUG).
Who is sponsoring clinical trial NCT03642626?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03642626 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03642626's enrollment target sits among peer trials
150 37th of 131 higher than 94 of 131 other Acute Lymphoblastic Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Lymphoblastic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RECRUITING · Phase 2
-
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RECRUITING · Phase 2
-
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI